NewsBenzinga문레이크 이뮤노테라퓨틱스, 화농성 한선염 치료용 나노바디 소네로키맙에 대한 생물의약품 허가 신청서를 FDA에 제출 문레이크 이뮤노테라퓨틱스, 화농성 한선염 치료용 나노바디 소네로키맙에 대한 생물의약품 허가 신청서를 FDA에 제출 Benzinga 2026.09.30 20:19 (GMT+0) Open on Benzinga Other news Here's How Much $1000 Invested In CF Industries Holdings 20 Years Ago Would Be Worth Today Transcript: Progress Software Q3 2026 Earnings Conference Call Eli Lilly Announces Detailed Results From The Phase 3 ACHIEVE-4 Trial Evaluating The Efficacy And Safety Of Foundayo; Foundayo Experienced A 16% Lower Risk Of MACE-4 And A 23% Lower Risk Of MACE-3, Meeting The Primary Objective For Non-inferiority... Here’s How Much You Would Have Made Owning CBRE Group Stock In The Last 15 Years Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today Transcript: Micron Technology Q4 2026 Earnings Conference Call
Eli Lilly Announces Detailed Results From The Phase 3 ACHIEVE-4 Trial Evaluating The Efficacy And Safety Of Foundayo; Foundayo Experienced A 16% Lower Risk Of MACE-4 And A 23% Lower Risk Of MACE-3, Meeting The Primary Objective For Non-inferiority...
